Clinical trials: Metastatic Carcinoma
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents.
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Trial name
- NCT06561685
- Testing
- LY4050784, Pembrolizumab, Cisplatin
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
SCC - Squamous Cell Carcinoma of Skin
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
- Trial name
- NCT04812535
- Testing
- Vilobelimab, Vilobelimab + pembrolizumab combination therapy
- Where
- 25 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- InflaRx GmbH
KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
The purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC).
- Trial name
- NCT07668752
- Testing
- GFH375, Docetaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Metastatic Clear Cell Renal Cell Carcinoma
Imaging Study in Metastatic Clear Cell RCC.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
- Trial name
- NCT07671417
- Testing
- RYZ512
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- RayzeBio, Inc.
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
- Trial name
- NCT05283226
- Testing
- NRC-2694-A, Paclitaxel
- Where
- 13 sites in United States, India
- Volunteers
- 21 people
- Sponsor
- NATCO Pharma Ltd.
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Nasopharyngeal Carcinoma
Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001 versus investigator's choice of chemotherapy in patients with advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02605967
- Testing
- Spartalizumab, Investigator choice of chemotherapy
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID)…
- Trial name
- OCEANII (NCT05195632)
- Testing
- Encorafenib, Binimetinib
- Where
- 34 sites in China, Taiwan
- Volunteers
- 63 people
- Sponsor
- Pierre Fabre Medicament
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 2 (NCT03382912)
- Testing
- Pegilodecakin, Nivolumab
- Where
- 35 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell
Safety Study of SEA-CD40 in Cancer Patients
This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma
- Trial name
- NCT02376699
- Testing
- Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- Seagen Inc.
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Solid Tumors, Metastatic Melanoma
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04140500
- Testing
- RO7247669
- Where
- 25 sites in Denmark, Georgia and 7 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or…
- Conditions
- Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Second-line Treatment, VEGF
- Trial name
- NCT01379534
- Testing
- TKI258
- Where
- 45 sites in United States, Brazil and 5 more
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876…
- Conditions
- Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
- Trial name
- NCT04881045
- Testing
- PF-07257876
- Where
- 43 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Pfizer
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Neoplasms, Neoplasm Metastasis
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for…
- Conditions
- Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT03166631
- Testing
- BI 891065, BI 754091
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.